Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04986852




Registration number
NCT04986852
Ethics application status
Date submitted
7/07/2021
Date registered
3/08/2021
Date last updated
18/11/2023

Titles & IDs
Public title
Olinvacimab With Pembrolizumab in Patients With mTNBC
Scientific title
A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer
Secondary ID [1] 0 0
PMC_TTAC-0001_06 / KEYNOTE-C14
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Triple-Negative Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Olinvacimab

Experimental: Olinvacimab (TTAC-0001) 16 mg/kg and Pembrolizumab (Keytruda®) 200 mg - Olinvacimab (TTAC-0001) 16 mg/kg on D1, D8 and D15
Pembrolizumab (Keytruda®) 200 mg on D1 Cycle: 3 weeks (21 days per cycle)


Treatment: Drugs: Olinvacimab
Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective response rate (ORR)
Timepoint [1] 0 0
Baseline upto 24 months
Secondary outcome [1] 0 0
Duration of response (DOR)
Timepoint [1] 0 0
Baseline upto 24 months
Secondary outcome [2] 0 0
Disease control rate (DCR)
Timepoint [2] 0 0
Baseline upto 24 months
Secondary outcome [3] 0 0
Progression-free survival (PFS)
Timepoint [3] 0 0
Baseline upto 24 months
Secondary outcome [4] 0 0
Overall survival (OS)
Timepoint [4] 0 0
Baseline upto 24 months

Eligibility
Key inclusion criteria
1. Female patients =19 years old

2. Histologically proven mTNBC* irrespective of PD-L1 status.

*Histological or cytological diagnosis of relapsed/metastatic TNBC. TNBC is defined by
the negative expression of estrogen receptors (ER), progesterone receptors and human
epidermal receptor-2 (HER2). If there is a pathology report of the metastasis, take
the histopathology of the metastases as standard. Negative for ER and progesterone
receptors is defined as the expression of ER and progesterone receptors in <1% of the
tumor cells by immunohistochemistry (IHC). HER2-negative is defined as a score of 0
and 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative. If
the HER2 test result is 0 or 1+ by IHC, FISH detection is optional, but the result
must be negative.

3. Has provided archival tumor tissue sample or newly obtained core or excisional biopsy
of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE)
tissue blocks are preferred to slides. Newly obtained biopsies are preferred to
archived tissue.

- Note: If submitting unstained cut slides, newly cut slides should be submitted to
the testing laboratory within 14 days from the date slides are cut

4. Has measurable disease per RECIST 1.1 as assessed by the local site
investigator/radiology. Lesions situated in a previously irradiated area are
considered measurable if progression has been demonstrated in such lesions

5. Has received at least one prior line of systemic therapy for metastatic or inoperable
locally advanced TNBC. Patients who have failed adjuvant chemo within 12 months should
be considered as fulfilling a line of systemic therapy.

6. No previous therapy with anti-VEGF, anti-VEGFR or anti-PD-1 antibody for their
metastatic disease. The use of anti-VEGF, anti-VEGFR, anti-PD-1 or anti-PD-L1 antibody
in neoadjuvant or adjuvant setting will be allowed if there was no progression of
disease within 6 months after the completion of treatment.

7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

8. Adequate hematologic, renal, and hepatic function tests performed within 7 days prior
to initiation of study treatment:

- Hematologic tests

- Absolute neutrophil count (ANC) = 1.5 x 109/L

- Platelets = 100 x 109/L

- Haemoglobin = 9.0 g/dL (This must be met without packed red blood cell
(pRBC) transfusion within the prior 2 weeks. Participants can be on stable
dose of erythropoietin, e.g. = approximately 3 months)

- Blood coagulation tests

- Prothrombin time (PT) = 1.5 x Upper limit of normal (UNL)

- Activated partial thromboplastin time (aPTT) = 1.5 x UNL

- Hepatic function tests

- Total bilirubin = 1.5 x UNL

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 x
ULN (= 5 x ULN in case of liver metastasis)

- Renal function test - Creatinine =1.5 × ULN or creatinine clearance (CrCl) =30
mL/min for patients with creatinine levels >1.5 × institutional ULN

9. HIV-infected participants must be on anti-retroviral therapy (ART) and have a
well-controlled HIV infection/disease defined as:

- Participants on ART must have a CD4+ T cell count >350 cells/mm3 at time of
screening

- Participants on ART must have achieved and maintained virologic suppression
defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of
qualification (below the limit of detection) using the locally available assay at
the time of screening and for at least 12 weeks prior to screening

- Participants on ART must have been on a stable regimen, without changes in drugs
or dose modification, for at least 4 weeks prior to study entry (day 1)

10. Participants who are HBsAg positive are eligible if they have received HBV anti-viral
therapy for at least 4 weeks and have undetectable HBV viral load prior to
randomization.

- Note: Participants should remain on anti-viral therapy throughout study
intervention and follow local guidelines for HBV anti-viral therapy post
completion of study intervention.

- Hepatitis B screening tests are not required unless:

- Known history of HBV infection

- As mandated by local health authority

11. Participants with history of HCV infection are eligible if HCV viral load is
undetectable at screening.

- Note: Participants must have completed curative anti-viral therapy at least 4
weeks prior to randomization.

- Hepatitis C screening tests are not required unless:

- Known history of HCV infection

- As mandated by local health authority

12. The patient should provide written informed consent
Minimum age
19 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment.

- Note: Participants who have entered the follow-up phase of an investigational study
may participate as long as it has been 4 weeks after the last dose of the previous
investigational agent.

2. Has known active CNS metastases and/or carcinomatous meningitis. Participants with
previously treated brain metastases may participate provided they are radiologically
stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging
(note that the repeat imaging should be performed during study screening), clinically
stable and without requirement of steroid treatment for at least 14 days prior to
first dose of study treatment

3. Treatment with systemic chemotherapy, hormonal therapy, immunotherapy or biologic
therapy within 4 weeks or five half-lives (which is shorter) prior to the baseline
visit

4. Has received prior radiotherapy within 2 weeks of start of study treatment. Patients
must have recovered from all radiation-related toxicities, not require
corticosteroids, and not have had radiation pneumonitis. A 2-week washout is permitted
for palliative radiation (=2 weeks of radiotherapy) to non-CNS disease

5. Not recovered below National Cancer Institute (NCI) CTCAE (v5.0) Grade 1 or baseline
from AEs due to previous therapy (patient with = Grade 2 neuropathy or alopecia may be
eligible)

6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior the first dose of study drug

7. Has an active autoimmune disease that has required systemic treatment in the past 2
years (i.e., with use of disease modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)
is not considered a form of systemic treatment and is allowed.

8. Has a known additional malignancy that is progressing or has required active treatment
within the past 2 years. (Note: Patients with basal cell carcinoma of the skin,
squamous cell carcinoma of the skin, or carcinoma in situ [e.g., breast carcinoma,
cervical cancer in situ] controlled by curative therapy are not excluded).

9. Has a history of (non-infectious) pneumonitis/interstitial lung diseases that required
steroids or current pneumonitis/interstitial lung disease

10. Has an active infection requiring systemic antibiotics

11. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric
Castleman Disease.

12. Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar
disorder etc.) or substance abuse disorder that would interfere with the participant's
ability to cooperate with the requirements of the study. Treated depression with
ongoing antidepressant medication is not an exclusion criterion

13. Female who is pregnant* or lactating and of childbearing potential who does not agree
to a reliable and adequate method of contraceptiona.

A women of childbearing potential (WOCBP) must agree to use contraception during the
treatment period and for at least 6 months (for females) after the last dose of study
treatment.

aAdequate contraception allowed in this trial is as follows

- Hormonal contraceptives such as combined oral contraceptive pill

- Intrauterine devices (IUD) or the implantation of intrauterine system

- Blockage methods (spermicides and condoms/spermicides and [vaginal] diaphragm for
contraception, vaginal sponges or cervical cap)

- Sterilization surgery such as tubal ligation in females *A WOCBP who has a
positive urine pregnancy test (within 72 hours) prior to treatment. If the urine
test is positive or cannot be confirmed as negative, a serum pregnancy test will
be required.

14. Uncontrolled hypertension (systolic blood pressure [SBP]> 150 or diastolic blood
pressure [DBP]> 90 mmHg) or seizure

15. Class III or IV heart failure by New York Heart Association (NYHA) classification

16. Requiring therapeutic anticoagulation treatment (prophylactic therapy with
low-molecular weight heparin is allowed)

17. Serious Grade 4 venous thromboembolic event including pulmonary embolism

18. Moderate to severe proteinuria as demonstrated by urine dipstick for proteinuria =2+.
For patients with =2+ proteinuria on dipstick urinalysis, a urine protein: creatinine
(UPC) ratio will be determined, or a 24-hour urine collection will be done. Patients
with a UPC ratio <1 or a 24-hour urine protein <1 gram are eligible.

19. History of abdominal fistula or gastrointestinal perforation, or serious GI bleeding
within 6 months

20. History of severe arterial thromboembolic event within 12 months of start of study
drug

21. Major surgery within 4 weeks prior to initiation of study treatment. (If the
participant had major surgery, the participant must have recovered adequately from the
procedure and/or any complications from the surgery prior to starting study
intervention).

22. A known history of severe hypersensitivity (=Grade 3) to study drugs and/or any of its
excipients.

23. Has had an allogenic tissue/solid organ transplant.

24. Unable to participate in the trial according to the investigator's decision.

25. Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines
that do not contain live virus are permitted

26. Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior
to enrollment

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/08/2026
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Hollywood Private Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
6009 - Nedlands

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
PharmAbcine
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The objective is to evaluate the efficacy and safety of Olinvacimab in combination with
Pembrolizumab in patients with mTNBC.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04986852
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Claire Beecroft, Ph.D, MD
Address 0 0
Hollywood Private Hospital, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
hyojin koh
Address 0 0
Country 0 0
Phone 0 0
070-4213-2925
Fax 0 0
Email 0 0
hyojin.koh@pharmabcine.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04986852